We provide you with 20 years of free, institutional-grade data for ANAB stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of ANAB. Explore the full financial landscape of ANAB stock.
| Reported Date | CIK | Ticker | Type | |
|---|---|---|---|---|
| 2025-08-06 | 1370053 | ANAB | 10-Q | Url |
| 2025-05-05 | 1370053 | ANAB | 10-Q | Url |
| 2025-02-27 | 1370053 | ANAB | 10-K | Url |
| 2024-11-05 | 1370053 | ANAB | 10-Q | Url |
| 2024-08-05 | 1370053 | ANAB | 10-Q | Url |
| 2024-05-09 | 1370053 | ANAB | 10-Q | Url |
| 2024-03-11 | 1370053 | ANAB | 10-K | Url |
| 2023-11-02 | 1370053 | ANAB | 10-Q | Url |
| 2023-08-07 | 1370053 | ANAB | 10-Q | Url |
| 2023-05-11 | 1370053 | ANAB | 10-Q | Url |
| 2023-03-01 | 1370053 | ANAB | 10-K | Url |
| 2022-11-08 | 1370053 | ANAB | 10-Q | Url |
| 2022-08-08 | 1370053 | ANAB | 10-Q | Url |
| 2022-05-04 | 1370053 | ANAB | 10-Q | Url |
| 2022-03-07 | 1370053 | ANAB | 10-K | Url |
| 2021-11-04 | 1370053 | ANAB | 10-Q | Url |
| 2021-08-09 | 1370053 | ANAB | 10-Q | Url |
| 2021-05-04 | 1370053 | ANAB | 10-Q | Url |
| 2021-02-25 | 1370053 | ANAB | 10-K | Url |
| 2020-11-04 | 1370053 | ANAB | 10-Q | Url |
| 2020-08-10 | 1370053 | ANAB | 10-Q | Url |
| 2020-05-06 | 1370053 | ANAB | 10-Q | Url |
| 2020-03-02 | 1370053 | ANAB | 10-K | Url |
| 2019-11-08 | 1370053 | ANAB | 10-Q | Url |
| 2019-08-08 | 1370053 | ANAB | 10-Q | Url |
| 2019-05-07 | 1370053 | ANAB | 10-Q | Url |
| 2019-02-28 | 1370053 | ANAB | 10-K | Url |
| 2018-11-08 | 1370053 | ANAB | 10-Q | Url |
| 2018-08-07 | 1370053 | ANAB | 10-Q | Url |
| 2018-05-08 | 1370053 | ANAB | 10-Q | Url |
| 2018-03-05 | 1370053 | ANAB | 10-K | Url |
| 2017-11-07 | 1370053 | ANAB | 10-Q | Url |
| 2017-10-10 | 1370053 | ANAB | S-1 | Url |
| 2017-08-10 | 1370053 | ANAB | 10-Q | Url |
| 2017-05-12 | 1370053 | ANAB | 10-Q | Url |
| 2017-03-08 | 1370053 | ANAB | 10-K | Url |
| 2015-09-09 | 1370053 | ANAB | S-1 | Url |
AnaptysBio, Inc(NASDAQ:ANAB) 
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. The company's products include Imsidolimab, an IL-36R antibody that inhibits the interleukin-36 receptor for the treatment of various derma...
Website: http://www.anaptysbio.com
Founded: 2005
Full Time Employees: 89
Sector: Healthcare
Industry: Biotechnology
The information provided in this report about ANAB stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.